ResearchThe Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States
ResearchSafety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial
ResearchAt-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial
ResearchSafety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
ResearchIntegrated Neurology Models for Population Health: Case Studies and Lessons From Academic Health Systems
ResearchTranscriptomic profiling uncovers mis-splicing and gene fusions in amyotrophic lateral sclerosis
ResearchOperational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the HEALEY ALS Platform Trial
ResearchA Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial
